

TranScrip Partners celebrates its first anniversary since foundation by appointing David Oxlade as Chairman of the Board

Appointments strengthen global healthcare expertise

4th November 2009 - TranScrip Partners LLP, a pharmaceutical development company providing expert advice and hands-on support to pharmaceutical and biotechnology companies across a wide range of therapeutic areas, today announces the appointment of David Oxlade to the position of Chairman of the Board. The appointment further enhances TranScrip's strategic corporate competencies.

David Oxlade is a pharmaceutical professional with extensive experience in the global health care industry. He spent many years in senior management and board level roles in the USA and Asia.

David is a former CEO of Xenova, the LSE and NASDAQ listed biotechnology company, and in 2006 was appointed Chairman of BioAnaLab, the analytical service organisation acquired in 2009 by Millipore Corporation. Prior to their acquisition by Roche, David spent 14 years working for Boehringer Mannheim and a further seven serving as President of Californian-based, Syva (a subsidiary of Hoechst AG),.

During his distinguished career, David has led significant innovations in the healthcare sector, including a revolutionary home blood glucose monitoring device for diabetics, creating the world's largest single diagnostic market segment. He established Cellmark Diagnostics to commercialise "DNA Fingerprinting"; a concept discovered by Professor Alec Jeffreys.

David is an Honorary Fellow of Brunel University, has held membership of the Emerging Enterprise Council of EuropaBio and the Bioscience Leadership Council since its inception. He has chaired the European Working Group of the Bioscience Innovation and Growth Team, set up by the UK Government under Sir David Cooksey to establish a ten year agenda for its bioscience industry.

Commenting on the appointment: Dr.Flic Gabbay, the Managing Partner of TranScrip, said: "We are delighted that David has agreed to serve as Chairman of the Board. He brings additional skills and expertise in the realm of global healthcare and adds new weight to our international credentials."

About TranScrip Partners

TranScrip is a rapidly growing firm of highly respected pharma industry and academic leaders, able to bring creativity towards fast-tracking and de-risking project, with maturing expansion plans for Europe and the world.

Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.

Collectively, TranScrip provides knowledge and operational capability in drug development in its widest context, working across multiple therapeutic and 'functional' areas. Already substantial by consulting group standards in the pharma space, it offers a flexible model that allows Clients to access Partners' capabilities to fill skill, experience and/or resource gaps, by integrating with and augmenting Client teams.

TranScrip Partners can provide specific individual experts or layered teams of experienced professionals, which can then evolve as required or as Client objectives change. It offers Clients the support of 'doers' who can think strategically and 'thinkers' who are happy to get their hands dirty.

Every Client project has leadership and oversight by the most appropriately experienced Partner to ensure "Best in Industry" standards, with built-in continuous professional development for all Partners that interims find hard to afford.

TranScrip Partners can provide:

- Multiple inputs from a variety of TranScrip staff for short, defined projects as well as long-term complex issues
- The full, integrated drug development knowledge of TranScrip Partners with an evolving mix of team members to ensure continuity of support across programme lifetimes

Website: <http://www.transcrip-partners.com>

For more information contact:

Tristan Jervis De Facto Communications +44 (0)20 7861 3019
t.jervis@defacto.com

Paul Branthwaite TranScrip Partners +44 (0)118 963 7846
paul.branthwaite@transcrip-partners.com